Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2-Reference-Cited by-同舟云学术

Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2

Published:2021-06-18 Issue:6548 Volume:372 Page:1336-1341
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Low Jun Siong¹^ORCID,Vaqueirinho Daniela¹^ORCID,Mele Federico¹^ORCID,Foglierini Mathilde¹^ORCID,Jerak Josipa¹,Perotti Michela¹,Jarrossay David¹,Jovic Sandra¹^ORCID,Perez Laurent¹^ORCID,Cacciatore Rosalia²^ORCID,Terrot Tatiana³,Pellanda Alessandra Franzetti⁴^ORCID,Biggiogero Maira⁴,Garzoni Christian⁴,Ferrari Paolo⁵⁶⁷^ORCID,Ceschi Alessandro³⁵⁸⁹^ORCID,Lanzavecchia Antonio¹⁰^ORCID,Sallusto Federica¹¹¹^ORCID,Cassotta Antonino¹^ORCID

Affiliation:

1. Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.

2. Laboratory of Immunogenetics, Department of Transfusion Medicine and Immuno-Hematology, Fondazione I.R.C.C.S. Policlinico S. Matteo, 27100 Pavia, Italy.

3. Clinical Trial Unit, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

4. Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.

5. Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.

6. Department of Internal Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

7. Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, New South Wales 2052, Australia.

8. Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.

9. Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.

10. National Institute of Molecular Genetics, 20122 Milano, Italy.

11. Institute of Microbiology, ETH Zürich, 8093 Zurich, Switzerland.

Abstract

Probing CD4 T cell immunity to SARS-CoV-2 A better understanding of CD4 + T cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial to the design of effective next-generation vaccines. Low et al. defined and estimated the CD4 + T cell repertoire of convalescent COVID-19 patients. After sorting various CD4 + T cell subsets, they generated numerous T cell clones that reacted to the SARS-CoV-2 spike protein. A large number of T cell clones from almost all individuals recognized a small conserved immunodominant region within the spike protein receptor-binding domain (RBD). The researchers isolated T cell clones that broadly reacted to the spike protein of other coronaviruses, providing evidence for the recall of preexisting cross-reactive memory T cells after SARS-CoV-2 infection. Science , abg8985, this issue p. 1336

Funder

Swiss National Science Foundation

Fondazione Cariplo

Helmut Horten Stiftung

Henry Krenter Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference31 articles.

1. The Immune Epitope Database (IEDB): 2018 update

2. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2